
Releases
ADMA Biologics Faces Securities Fraud Class Action Over Revenue Claims
Investors who incurred significant financial losses in ADMA Biologics, Inc. have until August 10, 2026, to apply as lead plaintiffs in a pending class action lawsuit. The litigation, initiated by the Law Offices of Howard G. Smith, targets alleged corporate misconduct spanning from August 2024 through March 2026.












.jpg)













